Phosphagenics Presents Transdermal Oxymorphone Data at Prestigious American Pain Society

5 May 2014, Melbourne: Australian drug delivery company, Phosphagenics Limited (ASX: POH, OTCQX: PPGNY), presented a poster on data relating to its TPM®/Oxymorphone patch at the American Pain Society 33rd Annual Scientific Meeting on 1 May 2014 in the United States.

The Society’s annual meeting is one of the most prestigious gatherings with scientists, clinicians and other pain professionals presenting the latest developments in reducing pain-related suffering and impacting pain management public policy.

The Company’s Chief Scientific Officer, Dr Paul Gavin, presented the poster, *A transdermal oxymorphone patch delivers therapeutic plasma concentrations of oxymorphone: an open label Phase I clinical trial*. The poster highlighted the exceptional clinical results announced in the 24 October 2013 release from the Company that demonstrated the delivery of oxymorphone through the skin at therapeutic levels.

The patch has been developed to target chronic pain. Chronic pain is pain that persists for more than three months. In the US alone over 75 million adults (about 20% of the total population) suffer from chronic pain. The estimated US economic loss from chronic pain in lost production and medical costs exceeds US$635 billion annually.

The target market for the TPM®/Oxymorphone patch is approximately $6 billion per annum.

“Expert feedback from a forum such as this is critical in ensuring that the product meets the needs and desires of future patients, prescribers, regulatory agencies and potential licensees. The oxymorphone patch was unique amongst the products under development that were presented at the APS,” said Dr Gavin.

Dr Janakan Krishnarajah, Principal Investigator for the oxymorphone trial at the Linear Clinical Research Facility, said:

“The results provide strong evidence that the Phosphagenics oxymorphone patch can achieve therapeutic concentrations of oxymorphone, which bodes well for the success of the patch as it progresses through later stage clinical trials.
Should this patch be successfully commercialised, it would be a valuable addition to the armamentarium that physicians currently have to manage the patient’s chronic pain condition.”

Poster abstracts (439) as in the American Pain Society Journal can be found at the following link: [http://download.journals.elsevierhealth.com/pdfs/journals/1526-5900/PIIS1526590014003782.pdf](http://download.journals.elsevierhealth.com/pdfs/journals/1526-5900/PIIS1526590014003782.pdf)

**Enquiries**

David Segal  
Investor Relations Manager  
Phosphagenics Limited  
+61 3 9565 1119

Rudi Michelson  
Monsoon Communications  
+61 3 9620 3333

**About Phosphagenics**

Phosphagenics Limited is commercialising drug delivery applications based on its novel transdermal (drugs administered via skin) TPM® – Targeted Penetration Matrix technology. TPM® is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products.

The lead products advancing through clinical trials are an oxymorphone and oxycodone matrix system for the relief of chronic pain. These products are part of a pain portfolio of currently five main products including a diclofenac patch and gel and a lidocaine patch.

Phosphagenics’ technology also has application in a diverse number of areas including animal health, bulk and branded cosmetic formulations and dermatological product solutions.

Phosphagenics’ shares are listed on the Australian Securities Exchange (ASX: POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (OTCQX: PPGNY).

[www.phosphagenics.com](http://www.phosphagenics.com)  
[www.bioelixia.com](http://www.bioelixia.com)